Application of MRI for Musculoskeletal Involvement in SLE

Hand Rheumatism Clinical Trial

— RMNLES  

Official title:

Application of MRI for Inflammatory Musculoskeletal Involvement in Systemic Lupus Erithematosus (SLE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04035265
• Other study ID #: RMNLES
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2018
• Est. completion date: May 2020

Study information

• Verified date: July 2019
• Source: Hospital del Mar
• Contact: Patricia Corzo, MD
• Phone: +34655057358
• Email: pcorzoreumatologia[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Articular involvement can reach up to 95% within the chronic multisystemic manifestations of SLE (1). Originally, a non-erosive pattern of articular inflammation was described, but the emergence of more sensitive imaging techniques, such as MRI (2, 3), show synovitis, erosions (hand: 47-48%, carpus 82-84% in SLE; and hand: 18%, carpus 97% in healthy individuals), bone oedema (hand: 4-5%, carpus 13-16% in SLE; and 0% in healthy individuals) and tenosynovitis (hand 47%, carpus 79%; not evaluated in healthy individuals) in patients with SLE (4, 5). Nowadays, a specific validated pattern of articular involvement associated with this disease does not yet exist, although it has begun to be studied. This research tries to evaluate the presence, frequency and distribution of inflammatory articular manifestations in SLE (erosions, bone oedema, synovitis or tenosynovitis) using MRI (6), with the objective of trying to establish a specific pattern for this disease, if it exists, that can shorten the diagnostic process. Moreover, it tries to characterise, if they exist, clinical differences between various patient groups according to their articular involvement.

Description:

BACKGROUND AND RATIONALE

• Nowadays no valid classification system for SLE-related arthritis/tenosynovitis exists.

• Data are not sufficient to establish an SLE-specific pattern of inflammatory involvement, similar to the pattern known for other inflammatory diseases such as rheumatoid arthritis (RA).

• Erosive arthritis associated with SLE has been typically related to patients that meet the criteria both for SLE and RA - syndrome known as Rhupus; but only a few data exist that classify erosive involvement of articular inflammation of pure SLE.

• No research exists that links the articular inflammatory pathology associated with SLE with its effect on quality of life (degree of fatigue and HAQ) or with the rest of manifestations and comorbidities associated with SLE.

• Being able to predict the development of SLE-related arthritis/tenosynovitis would be very useful when it comes to establishing the clinical management, treatment and prognosis of patients with SLE.

OBJECTIVES

• GENERAL:

• To describe the kind of inflammatory articular involvement (synovitis/erosions/bone oedema/tenosynovitis) (6,7) and its frequency in patients affected by pure SLE (excluding Rhupus, mixed connective tissue disease, overlap syndromes).

• SPECIFIC:

• To propose, if possible, an SLE-specific typical pattern of articular involvement.

• To establish clinical and serological differences (extra-articular manifestations, autoimmunity, treatment received, comorbidities and quality of life) according to the type of inflammatory articular involvement and in comparison to healthy individuals.

• To evaluate the possible link between SLEDAI/SLICC scores and the involvement using MRI.

HYPOTHESIS

• Patients with SLE have a specific inflammatory articular disease.

• A SLE-specific pattern of articular involvement exists.

• There are clinical and serological differences depending on the different patterns of articular involvement in SLE.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: May 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients affected by SLE (1982 revised criteria) with scheduled visits to the SLE specialized medical office at Hospital del Mar:

• (pain+ / synovitis +): SLE patients with inflammatory pain and synovitis determined by the practitioner during physical examination of radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP . Defining synovitis as pain and inflammation and/or deformity (present or existing over the past year) included in the clinical history

• (pain + / synovitis -) SLE patients with inflammatory pain without determined synovitis . Current (or over the past year) pain in radius and ulna carpal joint and/or carpus and/or metacarpophalangeal joint and/or IP, with no synovitis

• (pain - / synovitis -) SLE patients without inflammatory pain with normal physical examination currently or over the past year

• Control patients, without SLE nor immediate relatives affected by systemic inflammatory diseases, who lack articular pain and have blood test with no elevation APR or autoimmunity +)

Exclusion Criteria:

• Jaccoud's arthropaty

• RF + and/or ACPA +

• Incomplete SLE, MCTD, overlap syndromes

• Hand surgery

• Current neoplasia

• Non-rheumatoid systemic autoimmune diseases

• Contraindication for MRI

Related Conditions & MeSH terms

• Hand Rheumatism
• Lupus Erythematosus, Systemic
• Rheumatic Diseases
• Systemic Lupus Erythematosus Arthritis

Intervention

Procedure:
• Blood test
Carpus and fingers of non-dominating hand MRI with gadolinium contrast

Locations

Country	Name	City	State
Spain	Hospital del Mar	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Hospital del Mar

Country where clinical trial is conducted

Spain, 

References & Publications (6)

Ball EM, Bell AL. Lupus arthritis--do we have a clinically useful classification? Rheumatology (Oxford). 2012 May;51(5):771-9. doi: 10.1093/rheumatology/ker381. Epub 2011 Dec 15. Review. — View Citation

Boutry N, Hachulla E, Flipo RM, Cortet B, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. Radiology. 2005 Aug;236(2):593-600. Epub 2005 Jun 21. — View Citation

Haavardsholm EA, Østergaard M, Ejbjerg BJ, Kvan NP, Kvien TK. Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis. 2007 Sep;66(9):1216-20. Epub 2007 Mar 28. — View Citation

Mosca M, Tani C, Carli L, Vagnani S, Possemato N, Delle Sedie A, Cagnoni M, D'Aniello D, Riente L, Caramella D, Bombardieri S. The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. Autoimmun Rev. 2015 Jan;14(1):10-5. doi: 10.1016/j.autrev.2014.08.007. Epub 2014 Aug 23. — View Citation

Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, Shnier R, O'Connor P, Klarlund M, Emery P, Genant H, Lassere M, Edmonds J. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol. 2003 Jun;30(6):1385-6. Review. Erratum in: J Rheumatol. 2004 Jan;31(1):198. — View Citation

Tani C, D'Aniello D, Possemato N, Delle Sedie A, Caramella D, Bombardieri S, Mosca M. MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects. Skeletal Radiol. 2015 Feb;44(2):261-6. doi: 10.1007/s00256-014-2033-0. Epub 2014 Oct 24. Erratum in: Skeletal Radiol. 2015 Feb;44(2):267. Chiara, Tani [corrected to Tani, Chiara]; Dario, D'aniello [corrected to D’Aniello, Dario]; Niccolò, Possemato [corrected to Possemato, Niccolò]; Andrea, Delle Sedie [corrected to Delle Sedie, Andrea]; Davide, Caramella [corrected to Caramella, Davide]. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRI inflamatory changes	synovitis, erosions, bone oedema, tenosynovitis	1 to 2 months after clinical assesment
Primary	SLE activity scale	Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Measures last 10 days disease activity (rating (Y/N) 24 items related to specific manifestations on 9 organs) From 0 (best) to 105 (worst)	at clinical assesment
Primary	SLE treatments used	Number (n and %) of participants using any approved treatments for SLE used since diagnosis	at clinical assesment
Primary	Fatigue	Fatigue Severity Scale (FSS-9) Results from 9 (best) to 63 (worst): rating 9 items ranging from 1(best) to 7 (worst)	2 weeks before the performance of MRI
Primary	Quality of life scale	modified health assessment questionnaire (MHAQ): Results from 0 (best) to 3 (worst): rating 9 items from 0 (best) to 3 (worst) (results given divided by 8)	2 weeks before the performance of MRI
Primary	SLE damage scale	Systemic Lupus International Collaborating Clinics (SLICC) damage index: Irreversible damage rated by: 42 items related to 12 organs: 0 (absent-best)/1 (present-worst), some of them can count 2 or 3 (worst) if recidivant.; From 0 (best) to 46 (worst)	at clinical assesment
Secondary	Serological markers of disease activity: antinuclear antibodies (ANA)	ANA (dilution): given by titters (average titters comapred between groups)	6 months prior to 6 months after assesment
Secondary	Systemic SLE manifestations	presence of renal, lung, skin, neurological, haematological manifestations since diagnostic (Yes/No)	at clinical assesment
Secondary	Hand pain visual analogue scale (VAS)	VAS 0 (none) to 10 (maximum)	at clinical assesment
Secondary	Serological markers of disease activity: Anti-double stranded DNA antibody (DNAds)	Titters DNAds (UI/ml)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity: Anti-Smith antibodies (Sm)	Presence of Sm (Yes/No)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity: complement 3 (C3)	titters C3 (mg/dL)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity: complement 4 (C4)	titters C4 (mg/dl)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity: erythrocyte sedimentation rate (ESR)	ESR (mm/h)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity: C reactive protein (CRP)	CRP (mg/dl)	6 months prior to 6 months after assesment (the closest to MRI)
Secondary	Serological markers of disease activity:white cell blood count (WCBC)	WCBC: cellsx10E9/L	6 months prior to 6 months after assesment (the closest to MRI)